NCT06830629Phase 2Recruiting

A Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease

Study sponsor: Maze Therapeutics

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Primary completion2026-09Estimated
Enrollment · participants74Estimated
Source updated2026-07-27Last update listed in the registry record
Version history

Changes to this trial

Last 12 months
Pro unlocks the full available history and CSV export. View Pro features

· 1 field changed

Planned enrollment increased by 18 participants

− Before

56 participants (planned)

+ After

74 participants (planned)

Check registry source